Related Experiment Videos

Novel antithrombotic strategies in cardiovascular diseases

Paolo Golino1, Francesco Loffredo, Lucia Riegler

  • 1Division of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy. paolo.golino@unina2.it

Current Opinion in Investigational Drugs (London, England : 2000)
|April 9, 2005
PubMed

Insights

Atherothrombosis, a key factor in ischemic cardiovascular diseases, involves distinct arterial and venous thrombi. Novel antithrombotic therapies are emerging to target coagulation and platelet pathways for improved treatment.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Ischemic cardiovascular diseases are leading causes of mortality globally.
  • Atherothrombosis is central to the pathophysiology of these diseases.
  • Arterial and venous thrombi differ in composition and formation under varying shear conditions.

Purpose of the Study:

  • To review recent advances in antithrombotic research.
  • To highlight novel therapeutic strategies targeting atherothrombosis.
  • To discuss emerging compounds for coagulation and platelet pathways.

Main Methods:

  • Literature review of current research in antithrombotics.
  • Analysis of pathophysiology of arterial and venous thrombosis.
  • Examination of novel drug targets in coagulation and platelet function.

Main Results:

  • Existing therapies target coagulation and platelet function effectively.
  • New antithrombotic agents are being developed.
  • Research focuses on specific steps in coagulation cascade and platelet pathways.

Conclusions:

  • Significant progress has been made in developing antithrombotic strategies.
  • Novel antithrombotics offer potential for safer and more effective treatments.
  • Continued research is crucial in this rapidly advancing field.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...